A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa
Open Access
- 25 August 2025
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (3) , 826-829.e12
Abstract
No abstract availableKeywords
Funding Information
- Johnson and Johnson
This publication has 14 references indexed in Scilit:
- The epidemiology of hidradenitis suppurativa*British Journal of Dermatology, 2020
- A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and PainJournal of Investigative Dermatology, 2020
- Hidradenitis suppurativaNature Reviews Disease Primers, 2020
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa FoundationsJournal of the American Academy of Dermatology, 2019
- The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and DestructionJournal of Investigative Dermatology, 2019
- MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized StudyJournal of Investigative Dermatology, 2018
- Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaNew England Journal of Medicine, 2016
- Compartmentalized Cytokine Responses in Hidradenitis SuppurativaPLOS ONE, 2015
- Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatmentBritish Journal of Dermatology, 2014
- Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1α specific inhibitorMolecular Immunology, 1996